menu
    • menu
    [{"orgOrder":0,"company":"CBC Group","sponsor":"Adcentrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Antibody drug conjugate","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"CBC Group","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"1","companyTruncated":"CBC Group \/ CBC Group"},{"orgOrder":0,"company":"CBC Group","sponsor":"Hasten Biopharmaceutic","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"CBC Group","amount2":0.32000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"CBC Group \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"CBC Group \/ CBC Group"}]

    Find Clinical Drug Pipeline Developments & Deals by CBC Group

    Menu

    CBC Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CBC Group

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Hasten Biopharmaceutic

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

                            Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...

                            Brand Name : Edarbi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Azilsartan

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Hasten Biopharmaceutic

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CBC Group

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            CBC Group

                            Japan arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody drug conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Adcentrx Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Adcentrx Complete $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Resea...

                            Details : Series A financing is raised to power the development of next generation ADC for improving patient treatment options.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : Antibody drug conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Adcentrx Therapeutics

                            Deal Size : $50.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth